We next evaluated the predictive value of baseline (SVR12) GPC-3 for de novo HCC in cohort A. During a median FU of 37 (20–51) months, 63 (11.4%) patients from cohort A developed HCC (incidence rate: 3.83 cases per 100 person/years). This evidence concerns the gene GPC3 and hepatocellular carcinoma.